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Conducting polymer films offer a convenient route for the functionalization of implantable
microelectrodes without compromising their performance as excellent recording units. A
micron thick coating, deposited on the surface of a regular metallic electrode, can elute
anti-inflammatory drugs for the treatment of glial scarring as well as growth factors for
the support of surrounding neurons. Electro-activation of the polymer drives the release
of the substance and should ideally provide a reliable method for controlling quantity and
timing of release. Driving signals in the form of a constant potential (CP), a slow redox
sweep or a fast pulse are all represented in literature. Few studies present such release
in vivo from actual recording and stimulating microelectronic devices. It is essential to
bridge the gap between studies based on release in vitro, and the intended application,
which would mean release into living and highly delicate tissue. In the biological setting,
signals are limited both by available electronics and by the biological safety. Driving signals
must not be harmful to tissue and also not activate the tissue in an uncontrolled manner.
This review aims at shedding more light on how to select appropriate driving parameters
for the polymer electrodes for the in vivo setting. It brings together information regarding
activation thresholds for neurons, as well as injury thresholds, and puts this into context
with what is known about efficient driving of release from conducting polymer films.
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INTRODUCTION
Recent advances in the field of conducting polymers point out
their potential as drug delivery coatings from the surfaces of
microelectrodes. This is of interest considering it comprises an
opportunity to target cells in the close vicinity of an implant
with high spatial and temporal control of release. Glial scarring
is a physiological process that deteriorates electrode function by
forming a substantial barrier for signal transduction. Persistent
inflammation, following the scarring process, is believed to be the
reason why neurons are lost at the site of the implant further com-
plicating high resolution in recording and stimulation (Turner
et al., 1999; Szarowski et al., 2003; Biran et al., 2005). Systemic
treatment using anti-inflammatory drugs such as Dexamethasone
(Dex) has been suggested as a possible strategy for facilitat-
ing close integration of the implant with neural tissue (Spataro
et al., 2005). Conducting polymer electrodes designed to elute
drugs upon electro-activation are an alternative to systemic treat-
ment of glial scarring (Abidian et al., 2006; Wadhwa et al., 2006;
Evans et al., 2009; Richardson et al., 2009; Luo and Cui, 2009a,b;
Stevenson et al., 2010; Yue et al., 2013). Polymers in question
are mainly Polypyrrole (PPy), poly(3,4-ethylene dioxythiophene)
(PEDOT) but more recently also polyterthiophene (PTTh) has
been suggested as a candidate (Stevenson et al., 2010). This func-
tionality is until now almost exclusively studied in vitro. Here
we discuss this intriguing possibility, its requirements in terms
of electronic control of the implant, and the restrictions set by
electrochemical safety limits, to form the basis for continued
investigations in vivo.
Electro-activation is essential for triggering release but cannot
be allowed to cause detrimental effects on the cellular microen-
vironment. The conducting polymer electrode is not analogous
to a metallic electrode and direct currents can, and must, to
some extent be tolerated to drive drugs out of the electrode. On
the other hand, one must not overlook the possibility that by-
products form in body fluids as a result of electro-activation,
or that the neuronal circuitry is unintentionally activated, which
means that potentials must be kept within strict boundaries. The
solution that comes close at hand is to ensure that signals are
maintained below the activation threshold. Then the question
boils down to if this type of signal can be used to drive ionic drugs
out of the electrode? The majority of studies focus on release
by cyclic voltammetry (CV), a signal sufficiently slow to give
room for diffusion limited processes to contribute, in contrast
to fast stimulation pulses, generally designed to employ primarily
capacitive effects.
Studies show that release can be precisely managed by the
appropriate electrochemical driving signal. However, the means
to keep exact control of charge and voltage are limited in an
implant where three-electrode electrochemical systems are rarely
implemented. Furthermore, the circuitry designed for stimula-
tion in vivo cannot necessarily accommodate the same type of
measurements and control as the electrochemical potentiostat.
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Therefore, electronics and implantable reference electrodes that
meet this requirement need to be developed. If glial scarring
is really to be treated by the suggested method it cannot come
at the cost of connecting lab animals to fully functional exter-
nal potentiostats but the solution must come as a miniaturized
implant.
Finally we intend to outline the possibilities in terms of quanti-
ties of drugs that can be delivered and, to some extent, the variety
of drugs that could come in question. Most studies focus on deliv-
ery of the anti-inflammatory drug Dex but results point out that
other drugs with similar size and charge could also be potential
candidates.
In summary, we present the possibilities of conducting poly-
mer based release for glial scar treatment. Benefits of the method
will be put in perspective with design challenges that have to be
met from the electronics side. This information is essential for
enabling more studies to proceed to the implant stage, shedding
light on how to make the best out of this novel and exciting
concept.
ELECTRODEPOSITION OF CONDUCTING POLYMERS
Conducting polymers can be deposited on top of microelec-
trodes using an aqueous electrodeposition process. The reaction
is driven in a supporting electrolyte in which the monomer (M)
is dissolved or dispersed together with appropriate counter ions
(CI). The monomers oxidized at the surface of the working elec-
trode build up an insoluble layer of conducting polymer on its
surface. To maintain charge neutrality, the negatively charged CI
are at the same time electrostatically entrapped in the formed
material according to the following reaction:
M + CI−oxidize−→ (M)+CI− (1)
The nature of the counter ion is decisive for the ionic exchange
properties of the formed polymer (Bobacka et al., 2000; Jager
et al., 2000). The CI can be small or large, inorganic or
organic molecules, or a combination of several different neg-
atively charged molecules can be included in the supporting
electrolyte to form a more complex material. If a biologically rel-
evant molecule is used as counter ion, the formed polymer can
be biofunctionalized since the molecule is efficiently entrapped in
the porous polymer matrix yet still available for reactions on the
surface of the polymer material (Asplund et al., 2008). In addition
it can be released from the polymer upon altering the polymer
redox state.
There are some restrictions in the choice of biological ions
that can come in question for the counter ion incorporation
technique. The one step approach described above would work
exclusively for negatively charged biomolecules. For the deliv-
ery functionality to be efficient, a further constraint is that the
molecule must be sufficiently small to be able to diffuse through
the polymer matrix. It is difficult to give a precise estimate on
what could be considered as sufficiently small, since the poros-
ity is not an absolute property but can be influenced by the
electrodeposition process. To give some figure of merit, success-
ful release has been shown for molecules up to the range of
0.5 kDa. Although some authors report release of substantially
larger substances such as protein fragments, it is clear that this
is more challenging and might primarily rely on actuation of the
polymer material rather than electrostatic binding and release
(Thompson et al., 2006; Evans et al., 2009; Richardson et al.,
2009). This topic is discussed in detail in section Release Systems
and Mechanisms.
As an alternative to the direct incorporation in Equation 1, an
ion exchange approach can be used to drive ions into the already
formed polymer film for subsequent release upon reversing the
potential (Xiao et al., 2007). Furthermore, a carrier phase can be
introduced into the material by allowing the polymer to form
within a network of beads or fibers already containing the sub-
stance to be delivered (Abidian et al., 2006; Luo et al., 2011). A
non-charged substance in the larger size range, which is made
available in the supporting electrolyte, can be adsorbed to the
surface in parallel with the deposition process and thereby also
be mechanically entrapped although not electrostatically bound
(Asplund et al., 2008). All these methods could in principle lead
to amaterial with controlled delivery functionality similar to what
is accomplished with the direct incorporation technique. The
release dynamics can however be expected to differ. The focus
of this review is primarily on controlled release based on direct
incorporation according to Equation 1, although some results
based on materials using other methods are also included.
Dex DELIVERY—QUANTITIES AND EFFICIENCY
The theoretically possible inclusion of Dex in a polymer film,
based on the counter ion incorporation technique, can be esti-
mated by Equation 2 (Skotheim and Reynolds, 2006):
mdopant = Qdep
F
· γMdopant
2 + γ (2)
F stands for Faraday’s constant and equals 96485C/mol and Qdep
stands for deposition charge. With Dex as dopant, the com-
monly accepted assumption that the doping level γ = 0.3, and
the molecular weight of Dex, MDex = 392 g/mol, Dex inclusion
per charge consumed in the electrodeposition process would
be approximately 700μg/C. The deposition charge density that
would be considered reasonable varies, depending on the stability
of the polymer system, but 300mC/cm2 would clearly be within
the realistic range. This would mean a total included Dex mass
mDex = 210μg/cm2 according to Equation 2. Most likely higher
deposition charges could be used (Li and Huang, 2007).
A handful of papers point out the Dex levels that would be
required for efficient treatment of glial scarring. Based on the
assumption that the volume of interest could be defined as a
sphere of radius 500μm enclosing the electrode (Wadhwa et al.,
2006), and that an efficient concentration would be expected to
lie within the range 0.2–1μM (Golde et al., 2003; Shain et al.,
2003; Zhong et al., 2005), further assuming a microelectrode
radius of ∼15μm, the electrode would need to be able to deliver
a concentration of 6–30μg/cm2 from its surface.
Considering various papers report delivery of Dex in the range
3–126μg/cm2 in total, several single efficient doses would be
possible with the presented technology (Wadhwa et al., 2006;
Moulton et al., 2008; Stevenson et al., 2010; Sirivisoot et al.,
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2011; Xiao et al., 2012). In light of these values one might argue
that optimizing control is even more important than maximizing
output per pulse or sweep.
RELEASE SYSTEMS AND MECHANISMS
The drug delivery from a conducting polymer is a result of the
interplay between electrostatic interaction with the surround-
ing electrolyte, mechanical actuation of the film as a response
to the different swelling states upon redox, and conformational
changes in the polymer structure. To which extent each of the
mechanisms contributes varies depending on the film morphol-
ogy, the triggering signal and the use of any additional CI and
must therefore be evaluated separately for each case. Three types
of triggering signals are considered here namely redox sweeping,
constant potential (CP) and pulsing (Figure 1). Redox sweeping is
mainly referred to as the electrochemical measurement term CV.
The most simple release system would be a one-layer deposi-
tion where an anionic drug is included as a counter ion directly
in the deposition process. Assuming that the drug is thereby
homogenously distributed within the polymer film, and electro-
static interaction is the only responsible mechanism, the quantity
of drug that is released should be proportional to the applied
charge. This simplified view would imply that it is only the abso-
lute charge transfer over the interface that matters for the quantity
of drug delivered, regardless of if the charge is delivered as a pulse
or a sweep. However, this is a crude simplification for a vastly
more complex process (Kontturi et al., 1998; Majumdar et al.,
2008). In fact, experimental data shows that the dynamics of the
release signal greatly matters for the outcome.
In Table 1 a short compilation of release trigger signals and
experienced results from different conducting polymer based
release systems can be seen. Signals vary from steady potentials
over slow CV sweeps to faster pulsed signals. From the experi-
mental data reported in these studies it is evident that release is
not solely ruled by charge transfer. Multiple ions contribute to
charge transfer making the direct correlation of interfacial charge
transfer to delivery of a specific species less trivial (Pyo et al., 1994;
Jager et al., 2000; Pernaut and Reynolds, 2000; Li and Huang,
2007).
Some early work on PPy:ATP membranes gives important
insight into the different mechanisms responsible for CP based
drug delivery (Pyo et al., 1994; Pernaut and Reynolds, 2000).
Based on parametric studies on inclusion and release of Adenosin
Triphosphate (ATP), it was found that small, highly mobile
cations are initially driven into the film and first after sev-
eral minutes the release of ATP becomes the dominant process.
Furthermore, even though the dissociation of the ionic drug
from the polypyrrole chain may be fast, the actual release from
the film is driven by diffusion and is therefore a slow process
(Pernaut and Reynolds, 2000; Wadhwa et al., 2006; Li and Huang,
2007; Leprince et al., 2010). Fast signals would according to
these findings mainly result in exchange of small anions/cations
at the superficial layer of the polymer, for which the diffusion
coefficients are low.
The majority of studies report that CV is vastly more effi-
cient for driving release than CPs (Pyo et al., 1994; Pernaut
and Reynolds, 2000; Wadhwa et al., 2006; Li and Huang, 2007).
This underlines the complexity of the events involved in the
release process far beyond what can be accounted for by the
simplified electrostatic equation. The structural changes in the
polymer upon redox are expected to play a major part. Most
likely all the stored drug is not immediately accessible for release.
Diffusion of ions within the film, and rearrangement of the poly-
mer chains over time, exposes new deposits of drug that were not
immediately accessible for the first release attempt.
Electro-actuation contributes to such conformational changes
but in addition is expected to serve as a purely mechanical release
mechanism for any substance entrapped within the film (Abidian
et al., 2006; Thompson et al., 2006; Li and Huang, 2007). The
polymer film can both shrink and swell upon reduction depend-
ing on the size of the counter ion (Jager et al., 2000). For CI
in the intermediate size range such as Dex and ATP it is not
straight forward to predict which mechanism would dominate.
Nevertheless, repeated redox cycling will swell and shrink the film
interchangeably. Actively reversing the potential at a slow rate,
such as in CV, contributes to more efficient release for the anodic
cycle both through inner rearrangement and through mechanical
contraction of the matrix.
In summary, the efficiency with which interfacial charge trans-
fer can contribute to release of the intended drug depends on
the dynamics of the trigger signal. Furthermore, depending on
diffusivity and thickness of the individual polymer film, the
FIGURE 1 | The three different types of trigger signals for electrochemically controlled release that are discussed in the paper. The driving signal is
outlined in black and the follower signal in red.
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output of drug can be expected to vary. It is possible to alter
the electrodeposition protocol to achieve higher diffusivity of
the film, or even build layers with different properties to opti-
mize the active vs. passive release behavior for matching a certain
release protocol (Pernaut and Reynolds, 2000; Ge et al., 2009; Ru
et al., 2011; Jiang et al., 2013). Moreover, the effect of the purely
mechanical actuation can be further exploited by including pores
in the film, for instance by a templated electrodeposition process
(Abidian et al., 2006; Luo and Cui, 2009a; Luo et al., 2011). While
in early work, the systems studied were single layers, advanced
strategies to increase porosity of the films and boost their storage
capacity are more frequently reported in recent times. In a system
where entrapment is not solely based on electrostatic interaction,
the mechanical actuation could be expected to be the dominant
mechanism for release.
Despite the complexity of delivery mechanisms, one can make
a few general assumptions on which type of signal that would be
the most efficient for release from a polymer system regardless
of its structure. It is clear that the theoretical arguments speak in
favor for slow signals rather than fast pulsing, and especially for
CV which would allow both mechanical actuation and electro-
statics to contribute. There is a substantial risk that fast signals will
not lead to efficient transfer of the intended ions. Furthermore,
for a pulsed signal, the electrode will return to the open cell poten-
tial in between releases (mono-phasic pulsing) or even be actively
reversed (bi-phasic pulsing). This means each delivery will be
immediately followed by a signal actively driving the ionic flow
in the opposite direction. This could in theory mean a reuptake
of drug. However, the infiltration of small ions from solution
to replace the larger ions delivered is more likely. One way to
minimize the plausible reuptake of drug would be to allow the
molecules additional time to diffuse away from the surface and be
replaced by other ions at the reversed potential, speaking for the
introduction of an interpulse delay time.
It should be noted that despite all these points speaking for
active release with slow signals, release has been experimentally
proven also for systems with fast pulsing (Evans et al., 2009;
Richardson et al., 2009; Thompson et al., 2010). Thompson et al.
do not specifically report pulse duration, only that they use bipha-
sic stimulation delivered at a 5Hz frequency. Granted that this
means the full time was used for delivery of pulse trains this would
however mean PDs in the range of 100ms which is far from the
PDs that would normally be used to trigger neural activity. The
pulses reported by Evans et al. and also by Richardsson et al. come
closer to real stimulation parameters with pulse widths of 100μs
delivered at 250Hz (Evans et al., 2009; Richardson et al., 2009).
It should be mentioned that there was no dramatic difference
between active and passive release in the PPy/pTS/BDNF system
but clearly an effect for the PPy:pTS:NT3 system. This would
speak for a release controlled by conformational changes of the
polymer rather than an electrostatic driving force. The authors in
addition argue for that changes in hydrophobic properties of the
polymer matrix would contribute to release in this case.
The CV ranges reported vary widely. The lowest vertex poten-
tial reported is at−1V and the highest vertex potential at 1.4 V vs.
Ag:AgCl. Commonly, only the anodic part of the sweep is used.
It has also been pointed out that the scan rate further influences
release efficiency of the single CV (Leprince et al., 2010). Sweep
rates reported are in the range of 10–100mV/s. For the constant
potential driven systems, the potentials required to actively drive
release are in the range of −0.3 to −0.5 V vs. Ag:AgCl. Clearly
this will depend on the nature of the ionic drug, which conduct-
ing polymer that is used and the morphological properties of the
individual polymer layer.
To some extent, a conducting polymer film that is physically
degrading upon electrochemical stress can also act as a controlled
delivery system. As the film falls apart, molecules that were immo-
bilized in the structure are released at a rate that can be controlled
by the level of stress. The weakest link is often the adhesion to the
underlying substrate leading to complete or fragmental delamina-
tion, depending on the film cohesion. It might be difficult to judge
whether a certain system performs delivery based on actuation,
electrostatic interactions or simply by degradation, something
that might be less favorable with an electrode intended for long
term use, by only studying the release of the intended species.
Ideally, one should therefore analyze if other molecules or par-
ticles are expelled from the film in parallel to the drug (Boehler
and Asplund, in press). It should also be noted that conducting
polymers degrade by over-oxidation meaning that the electronic
structure is disrupted leading to a non-conducting material. PPy
is more vulnerable to over-oxidation than PEDOT, and also the
counter ion has an influence on the electronic stability (Yamato
et al., 1995; Thaning et al., 2010). For this type of degrada-
tion the material itself remains at the electrode but progressive
over-oxidation will influence the ion conducting properties and
thereby the delivery mechanism over time.
RELEASE TRIGGER SIGNALS—FROM THE SIDE OF
BIOLOGICAL SAFETY
In the previous section, the efficiency of the three release signals
was discussed. However, other practical aspects such as the avail-
ability of devices capable of delivering these signals, as well as the
safety for the biological environment, should naturally be taken
into consideration. In the following section, the three trigger sig-
nals in Figure 1 are therefore discussed with regard to the safety
of neurons.
In general, the restrictions that would apply to a signal to be
applied in vivo could be summarized as follows:
1. The signal transfer should take place through reversible pro-
cesses which do not lead to the formation of electrochemical
by-products in the tissue or corrosive reactions at the elec-
trode.
2. The signal must not trigger undesired activity in the neural
network.
3. The signal must not induce damage to neurons.
These conditions do not completely apply for the situation where
the aim is to use the signal to drive controlled release. In this case,
ideally the trigger signal should be designed to be practically invis-
ible from the side of the neuron, yet still be efficient for pushing
out drugs in a reasonable time frame and with good control of the
delivered amount. While restriction 1 is of the utmost importance
for metallic electrodes it is not directly transferrable to polymer
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electrodes. The aim is to exchange the ionic drug in the polymer
for other ions naturally available in tissue so irreversibility is to
some extent here a necessity. However, the limitation of the elec-
trode potential to prevent redox reactions in proteins and water
as well as pH-shifts is a must.
It is also highly desirable that the signal used for drug release
does not result in undefined excitation of surrounding neurons as
in restriction 2. Normally, when evaluating how to stimulate neu-
ral tissue, the ambition is to assemble signals that are efficient in
precise activation of a defined population of cells at current/pulse
durations chosen to induce minimal electrochemical stress on the
electrode. For the drug release approach, the signal needs to be
optimized from close to the opposite perspective. The ambition
would be to use a release signal that does not substantially influ-
ence surrounding cells but is efficient in pushing drugs out of the
electrode.
Last, but not least, it is well-known that electrical stimulation
of neurons can induce cellular injury even when the delivered
stimulation is well within the boundaries given by the electro-
chemical safety (Shannon, 1992; Veraart et al., 2004). Normally
such effects do not occur below the levels which can trigger neural
activity which would ensure that a signal that confines to con-
dition 2 is a conservative limit also for restriction 3. However,
these injury thresholds are most of the time given with consider-
ation to the pulsing parameters that would be considered normal
for neural excitation. It is therefore advisable to take a closer
look at the safety boundaries from this perspective when more
unconventional pulsing parameters might be put into use.
PULSING
A standard pulse for recruitment of intracortical neurons would
be a biphasic train of rectangular pulses of constant current
delivered at a frequency in the range of 100–400Hz, commonly
around 200Hz (see Figure 1). The minimum current strength
needed to excite neuronal tissue (threshold current, Ith) depends
on the pulse duration (PD) as in the strength-duration relation-
ship depicted in Figure 2. PD should as a rule of thumb be chosen
close to the chronaxy of the intended target tissue which in prac-
tice means durations in the range of 100–300μs for myelinated
nerve fibers. Longer pulse durations would not be energy efficient
for activation of neurons and in addition would increase the prob-
ability for non-reversible corrosive processes at the electrode site
(Tehovnik, 1996).
When stimulating at PDs close to the chronaxy, typical thresh-
old currents for neural activation would be estimated to be
around 10μA, but recent studies show that actual activation
thresholds can be expected to be even lower than 4μA (reported
for 200μs PD and 250Hz) (Tehovnik et al., 2006; Histed et al.,
2009). Since the objective of the PEDOT electrode is drug delivery
rather than activation, stimulation should be kept below thresh-
old not to evoke neural activity unintentionally. In practice and
according to the generally accepted current-duration relationship,
this leaves two alternatives (Tehovnik, 1996). Either shortening
the pulses to increase the threshold current, or use longer pulses
and stay well-below the rheobase. For a pulse substantially longer
than the chronaxy this means at least below 2μA, preferably even
lower. The longer the pulse, the more charge would be expected
FIGURE 2 | Strength-duration relationship for excitable tissue. Red line
shows the threshold current, Ith, at which neuronal tissue is excited for a
rectangular stimulation pulse of duration PD.
to be required to activate neurons. This clearly rather speaks for
maximizing charge and thereby possibilities for ionic delivery by
driving longer pulses at lower currents.
If a small and highly local amount of activated neurons can
be tolerated, currents can naturally be set higher. This is some-
thing that would have to be evaluated with respect to the exact
placement of the particular electrode. With knowledge of the
excitability constant, K, of the target tissue, efficient spread of
stimulation can be estimated, over the radius r, for a given case
according to I = K∗r2 (Tehovnik, 1996; Tehovnik et al., 2006).
This would provide a reasonable estimate for the volume of cells
affected by a pulse if exceeding the threshold in the given case.
Tissue damage can occur as a consequence of inappropriately
chosen stimulation parameters, even though the given stimula-
tion is within the electrochemical safety limits of the electrode
material. It is broadly accepted that important factors to con-
sider are charge per phase and charge density delivered from the
electrode (McCreery et al., 1990; Shannon, 1992). The mecha-
nisms behind such effects are not completely understood but it
is believed that electroporation is a main contributor to this kind
of tissue damage as well as mass action phenomena, for instance
depletion of oxygen or glucose, or excessive release of glutamate,
caused by local neural overactivity (Merrill et al., 2005). Since sig-
nals in the case discussed here should be chosen with the aim not
to induce neural signaling, only electroporation would need to be
considered.
Taking also restriction 3 into account, there is reason to ask
if there is a risk for the occurrence of electroporation based on
this type of pulsing? A detailed insight into how the threshold for
electroporation can be expected to vary with other stimulation
parameters is given by Butterwick et al. (2007). One conclusion
of their work is that, for longer pulses (PDs in the range of ms),
the threshold current density at which electroporation can be
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expected to occur is lower than for shorter pulses. The thresh-
old current density scales with PD approximately as 1/sqrt(PD).
It is also clear from their results that with pulsing frequencies
exceeding 50Hz repetition frequency thresholds are significantly
lower than for single shots. For electrodes smaller than 300μm
it is further concluded that total current would be the main lim-
itation, and injury thresholds would not to the same extent be
influenced by current density as is seen with the larger electrodes.
Their results are based on measurements in chicken retinas but
correlate well to measurements in earlier work concerning injury
thresholds in cortical tissue (McCreery et al., 1990; Shannon,
1992; Veraart et al., 2004). It is therefore assumed that the safe
limits reported would be a reasonable figure of merit for stimula-
tion of any target tissue in the central as well as in the peripheral
nervous system.
The lowest threshold where stimulation induced damage was
detected in their experiments was determined to be 61mA/cm2
at a pulse duration of 6ms for repetitive pulsing (>50Hz).
Translated to a microelectrode of 50μm that would correspond
to a charge per pulse of 7.2 nC. However, for pulses shorter
than the ms, threshold currents are substantially higher. Deduced
from the data presented by Butterwick, for the 600μs, expected
thresholds would rather be in the range of 0.2 A/cm2. Due to
the shorter pulse length this would in fact mean a lower charge
per phase threshold, for the 50μm electrode 2.3 nC/phase. This
would speak for that electroporation could occur even with a
minor elevation of the stimulation current.
The study also presents results regarding the influence of the
size of the electrode and the values cited above relate to a large
electrode, not a microelectrode. If taking their results concern-
ing microelectrodes into account, here smaller than 300μm in
diameter, the threshold charge per phase that could safely be
delivered did in fact not depend on electrode size. The small-
est electrode used in their experiment was ∼100μm in diameter
and the threshold, when investigated on the retina cells using
600μs single pulses, were found to be ∼70 nC per phase. This
threshold should, according to their theory of size independence,
also be valid for smaller electrodes. Even though these particular
results describe thresholds for one single pulse, there is substan-
tial margin to the 1.2 nC given by the 2μA and 600μs suggested
as suitable sub-threshold stimulation (second paragraph, section
Pulsing).
In summary, also from the perspective of restriction 3, it would
be recommendable to work with PDs longer than the chronaxy. It
further appears as if PDs are on the longer side, and threshold
current is estimated to be below the rheobase, there is no sub-
stantial risk for disruption of cellular membrane integrity as a
consequence of the pulsed trigger signal.
In order to establish boundaries for safety it is of interest to
glance at the field of deep brain stimulation (DBS), where intra-
cortical stimulation has been therapeutically used over more than
a decade. The technology is FDA approved and one could thereby
argue that these stimulation protocols have already been proven
safe for use in patients. Kern and Kumar (2007) report common
values for the Sub Thalamic Nucleus (STN)DBS to be in the range
130–185Hz with typical pulse durations of 60μs. However, the
extremely short pulse durations used for DBS are most likely not
efficient for drug expulsion. Release relies to large extent on slower
processes as has already been discussed in the previous section.
CYCLIC VOLTAMMETRY
It has already been pointed out that slow redox sweeping of the
electrode has been found efficient for delivery of ionic drugs.
The stimulation effects of CV in brain tissue are not specifically
addressed in the literature. Theoretically, if the current-duration
curves are extrapolated into infinitely long pulses, which would
be a reasonable approximation for the smooth transitions of a CV
curve, the suggestion would be that as long as the current is still
below the rheobase the neurons would not be excited.
If the neuronal activity is not directly influenced, the restric-
tions would rather be set by the possibly detrimental electrochem-
ical reactions that could occur as a by-product of any excessive
voltage. The two parameters to consider are the vertex potentials
and the sweep rate. The non-conservative constraints for the ver-
tex potentials would be given by the water window (−0.6 V to
0.8 V vs. Ag:AgCl) since the evolution of hydrogen (−0.6 V) and
oxygen (0.8 V), respectively, would occur at the electrode upon
exceeding this window. Over-oxidation of PEDOT would not be
expected to occur at voltages lower than 1.1 V and is therefore
not a limiting factor in this case. This is however not sufficient
to support that no other electrochemical reactions of importance
take place within this window. Furthermore, appropriate refer-
ence electrodes are often not available in the implanted situation
meaning that possible variations in applied voltagesmust be taken
into account. Materials do either not deliver a stable potential in
chronic implantations or biofouling clogs pores in ion-selective
membranes.
One example on actual parameters used in a similar biological
setting can be found in recent work monitoring electrochemical
characteristics of implanted electrodes. Kane et al. (2011) employs
the full water window at a sweep rate of 50mV/s for their in vivo
CV investigations and do not report any adverse tissue response
as a consequence. In the sensor literature, fast CV is often sug-
gested for instance for in vivo monitoring of neurotransmitters.
It should be noted that so far sweep rates used are in the range
of 300V/s and thus far beyond what has been proposed for drug
release (Pihel et al., 1996). The biological response was not the
primary target for the analysis in either study and was therefore
not carefully observed. Scans used for analytical purposes in an
experiment with a sedated animal, and limited to a few occa-
sions, are not necessarily suitable for repeated use in proximity
of a population of highly sensitive cells. In both studies animals
were anaesthetized which might not be possible to perform on a
bi-weekly to weekly basis needed to support efficient drug release.
BIAS POTENTIAL
A bias potential of approximately −0.5 V vs. Ag:AgCl could be
used to drive drug release. Cells are not expected to respond
adversely to a steady potential if kept within reasonable bound-
aries. For instance, a positive interpulse bias potential of 0.6 V has
been suggested as a method for boosting performance of iridium
oxide electrodes and has been applied to SIROF coatings in vivo
(Cogan et al., 2006; Kane et al., 2011). The authors comment
that the long-term consequences of the low net current needed to
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maintain the bias potential has not yet been explored. However,
for the drug release, the bias potential would only be applied at the
specific occasions where drug release is requested which qualifies
as a limited time frame and should be safe for use.
DISCUSSION
OTHER RELEASE STRATEGIES AND DRUGS
Apart from Dex, also various other anti-inflammatory drugs like
α-MSH, IL-1-RA, or heparin have been proposed in literature
for treatment of inflammatory reactions. These molecules tar-
get different receptor pathways in the inflammation cascade and
can thus be interesting alternatives or complements to the Dex
(Bridges and Garcia, 2008; Go et al., 2012). All of the listed
molecules are typically delivered from passively eluting systems
due to their chemical properties and overall size, which makes
them incompatible with the ion-exchange principle provided by
conducting polymers. In contrast, Dex is in the appropriate size
range (392Da) and features an anionic charge characteristic,
which makes is eligible for both passive and actively controlled
release systems. Furthermore, Dex is known to be the most
potent glucocorticoid drug for anti-inflammatory treatment due
to its effect in multiple receptor pathways, which reveals this
drug as first choice for the realization of an anti-inflammatory
drug eluting system for treatment of the glial scar. For a more
detailed description of relevant molecules and their impact on the
adverse host response to implanted biomedical devices the excel-
lent review by Bridges et al. is strongly recommended (Bridges
and Garcia, 2008). It should be mentioned that it would be
possible to use a deposition technique not relying on direct incor-
poration to combine the active delivery approach also with these
substances (Abidian et al., 2006; Luo et al., 2011).
It is a valid question to ask how the actively controlled release
of Dex from a microelectrode would compare to a delivery coat-
ing passively leaking Dex into tissue, or systemic treatment (Shain
et al., 2003; Spataro et al., 2005; Zhong and Bellamkonda, 2007).
The latter has the clear downside of requiring much higher total
doses distributed to reach an efficient concentration at the point
of interest and side-effects would thus be a main concern. In situ
delivery, avoiding the counterproductive neuroendocrine feed-
backs, is from this perspective clearly beneficial regardless of if
the system is based on a passive or active release approach.
The active release system offers controllability but for a limited
quantity whereas the passive system can cover the complete sur-
face of a probe, thereby storing a much larger quantity, but hold
few options to influence release dynamics. From the data available
in literature it is difficult to judge whether such a system would
be more successful in mitigating inflammation than the actively
triggered release approach. The answer to this question could
only be given if the necessary time course of the treatment was
known. It is still an open question whether the anti-inflammatory
treatment over the time course of a month, which would be the
critical period in which the scar forms, influences the state of
the surrounding tissue also in the long term (Szarowski et al.,
2003; Biran et al., 2005; Potter et al., 2012). If it does, the lower
quantity delivered by the microelectrodes might still be sufficient,
meaning higher drug load is not a substantial benefit but could
be traded for more precise release control. On the other hand,
treatment might be needed for a much longer time period which
would make the opportunity to load a higher quantity of drug
much more attractive. A certain control of release dynamics in
the passive release system could still be accomplished by care-
fully tailoring the degradability properties of the release matrix.
In theory, nothing speaks against that such a system in the future
could include certain responsiveness to biological factors, for
instance react to chemical factors present for a higher degree of
inflammation, by increasing the release rate.
It should be noted that such a delivery matrix, which can act as
the golden standard for passive release, does not yet exist. Thus,
the passive release system relies on substantial development in this
direction in the same way as the polymer electrodes hold room for
future optimization. Recent result show that also surface immo-
bilized Dex might have an effect for improving probe integration
which illustrates the need for further work to elucidate the under-
lying mechanisms involved in the tissue response to Dex (Grand
et al., 2010). In summary, the passive delivery approach should be
pursued in parallel with the active delivery systems, as an interest-
ing alternative or even additional approach, since the use of the
one delivery system in fact does not exclude the use of the other
as a complement.
RELEASE TRIGGER SIGNALS—CONCLUDING REMARKS
Taking all the considerations regarding efficiency and safety into
account they all speak in favor for slow release signals. CV seems
to be the most suitable from the efficiency perspective and most
likely a moderate use of voltammetric sweeping will not be harm-
ful to tissue or lead to undeliberate excitation of the neuronal
network. This however needs to be confirmed in experiments.
In practice, the equipment needed to perform well-controlled
CV at the implant site might however not always be avail-
able. Proper CV measurements require a three-electrode electro-
chemical control system and the technologies for on-probe inte-
gration of stable reference electrodes on implants are not yet
established (Tolosa et al., 2013).
Considering this practical aspect, it might therefore still be the
most convenient to use a pulsed signal for release rather than a
sweep. In this case it would be advisable to aim for low currents
and PDs significantly longer than the chronaxy. Furthermore, to
present as little stress as possible to the tissue, low pulsing fre-
quencies should be used. Lowering the pulsing frequency and
compensating by extending the overall stimulation time should
have little effect on the release itself but would allow higher
currents before stimulation induced damage to neurons can be
expected to occur (Butterwick et al., 2007). Charge balance is not
a necessity for this kind of drug release. On one hand it might
contribute to increased actuation, on the other hand it might be
counterproductive if the Dex ions are immediately retrieved by
the reversed pulse. An interpulse delay could mitigate the second
effect.
One possibility to, with a simple device, imitate the effect
of a CV is to exchange the sweep with interchangeable voltage
steps, set to the upper and lower vertex potential. Microsized
devices capable of maintaining a fixed voltage vs. a reference, and
suitable for implantation, have been described by others (Islam
et al., 2010). In Figure 3, the current response of a PEDOT:Dex
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electrode to a cyclic voltammogram can be seen as well as the cur-
rent response to a rectangular pulse. It is clear that the current
flow follows another scheme than in the carefully controlled slow
CV. What this in practice would mean for the drug release should
be further investigated experimentally.
Finally, not only efficiency of release but also controllability
should be considered. For the application, it is desirable that a
precise dose of Dex can be delivered at each attempt, whichmeans
the response to the trigger signal must be predictable. Taking the
complexity of events involved in release into account, such one
to one correlation is not trivial to accomplish. More likely, the
response of the polymer will change over time and with each
delivery attempt, something that must be carefully considered to
ensure the trigger signal has the intended effect throughout the
full experimental time frame. This needs to be further investigated
before a specific polymer delivery system is put into use.
Since the drug delivery systems reviewed here are intended for
local treatment targeting only the cells in the immediate vicinity
of the electrode, it is highly desirable that the very same elec-
trode used for delivery can still function as a neural interface.
For recording this is not expected to be a problem since both
PEDOT and PPy are known for their low impedance in this
respect. Although the drug delivery electrodes in general are out-
performed by the regular surfactant based conducting polymer
materials in terms of impedance, it has repeatedly been shown
that also drug containing conducting polymer electrodes still
lower the impedance in comparison to a bare metallic surface
(Wadhwa et al., 2006; Luo et al., 2011).
FIGURE 3 | A comparison between the current response to a swept
voltage vs. a stepped voltage for a PEDOT:Dex delivery system.
Measurement was performed in PBS and vs. an Ag:AgCl reference.
For stimulation the central question would be if stimula-
tion can be performed without unintentionally triggering release?
From the literature reviewed here it is not possible to make a
conclusive statement on whether this would at all be possible.
As discussed, some authors do indeed present release based on
the type of fast pulsing that would be common to use for stim-
ulation purposes (Evans et al., 2009; Richardson et al., 2009).
However, it can be concluded that slow sweeps are vastly more
effective for drug release (Table 1) and several authors report
that they need to reach a certain voltage before actual release is
triggered (e.g., Pyo et al., 1994; Pernaut and Reynolds, 2000). It
is plausible that smart materials design can further exploit this
effect making the release-free stimulation possible within certain
boundaries.
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